AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...

Recent data from the National Cancer Institute (NCI) suggest that the number of people in the US diagnosed with diffuse large ...

National health spending is forecast to approach $9 trillion by 2034, increasing faster than GDP and consuming 20.6% of the ...

On National HIV Testing Day, getting tested remains a gateway to prevention and treatment, but improving access alone is not enough. Expanding access to PrEP, PEP, pharmacists, long-acting therapies, ...

How longer-lasting therapies cut injection burden, boost adherence, and protect vision in AMD, DME, and RVO with ...

Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

Interrupted time-series signals showed exacerbations increased before 2015 but dropped sharply after 2015 and continued ...

Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...